Dr Eleanor Cheadle (PhD, BSc (Hons), FHEA) - research
My research interests lie in immunotherapy of B-cell malignancies. I am particularly interested in ways to improve the generation of effective anti-tumour T-cell immune responses post anti-CD20 monoclonal antibody therapy. My research currently focuses on a number of ways to improve anti-CD20 mAb therapy such as combining therapy with immunomodulatory agents, radiation and manipulation of the tumour microenvironment. We are particularly interested in the novel type II anti-CD20 mAb Obinutuzumab and how its mechanism of action compares to type I rituximab. I am also interested in adoptive cell therapy, in particular gene modified T-cells expressing CD19 specific chimeric antigen receptors.
Collaborators and affiliated staff
- Improving CAR T Cell Therapy to Treat CD19+ Malignancies.
- Increasing the Efficacy of Anti-CD20 Antibody Therapy and Improving Outcome in B-Cell Response Malignancies by Enhancing the Anti-Tumour Immune Response.
- Increasing the efficacy of the type II anti -CD20 mAb GA101 by enhancing the anti-tumour immune response in the hCD20 transgenic mouse model
- Preparation and Testing of a Recombinant BCG Vaccine for Childhood ALL Expressing the TEL-AML1 (ETV6-RUNX1) Oncoprotein.